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Introduction
Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease primarily characterized by chronic 
inﬂ am mation of the exocrine glands, in particular the 
salivary and lacrimal glands. Extraglandular manifes-
tations occur in many patients and may involve almost any 
organ. B-lymphocyte hyperactivity in pSS is mani fested by 
the presence of anti-SS-A and anti-SS-B antibodies, 
rheumatoid factor, type 2 cryoglobulins, and hypergamma-
globulinemia. Prolonged B-cell survival and excessive 
B-cell activity, probably related to increased production of 
B-cell activating factor (BAFF) [1], may even lead to 
mucosa-associated lymphoid tissue lympho mas occurring 
in 5% of Sjögren’s syndrome (SS) patients [2,3].
Despite systemic B-cell hyperactivity, analysis of lesional 
tissue in the salivary glands shows a predomi nance of T 
lymphocytes surrounding ductal epithelial cells. Th e 
majority of these T cells (70 to 80%) are CD4-positive and 
show an activated phenotype. CD8-positive T cells with 
cytotoxic activity, as manifested by their expression of 
granzymes, constitute around 10% of inﬁ l trating cells. Th e 
remaining inﬁ ltrating cells are B lymphocytes [4].
Th ese data demonstrate that, on the one hand, systemic 
B-cell hyperactivity is a dominant feature of pSS, but that, 
on the other, T lymphocytes targeting glandular epithelial 
cells are involved in lesion development. As mentioned 
above, the majority of these T cells are CD4-positive and 
express cytokines, such as IFNγ and TNFα, classically 
considered characteristic for Th 1 cells. Lesional tissue 
also shows B-cell activity, however, among others in 
terms of local production of anti-SS-A and anti-SS-B 
autoantibodies and formation of ectopic germinal center-
like structures. Th 2 cytokines, such as IL-6 and IL-10, are 
also present. Furthermore, local IFNα production has 
been demonstrated that induces expression of BAFF by 
both inﬁ ltrating cells, such as monocytes and dendritic 
cells, and resident epithelial cells. Local production of 
BAFF may underlie B-cell hyperactivity and prolonged B-
cell survival.
Th e complexity of the pathogenetic pathways involved 
in pSS as described above, and as further elaborated in a 
number of excellent reviews [5-7], makes it diﬃ  cult to 
deﬁ ne which eﬀ ector mechanisms are fundamental for 
development, persistence and progression of the inﬂ am-
matory process in the exocrine glands of patients with 
pSS. During the past two decades, biologicals have 
become available that target speciﬁ c cells or cytokines 
that are instrumental in physiological or pathological 
immune responses. Targeting and elimination of certain 
cells or cytokines may indicate their speciﬁ c role in 
lesion development in pSS. Th e current review will 
discuss what clinical trials with biologicals have taught 
us about the pathogenesis of pSS. Attention will be 
given not only to the direct clinical results of these 
trials, but also to the mechanistic eﬀ ects of these 
biologicals on pathways considered to be involved in the 
(immuno)pathogenesis of pSS. Table 1 presents a 
Abstract
In vitro and in vivo experimental data have pointed 
to new immunopathogenic mechanisms in primary 
Sjögren’s syndrome (pSS). The availability of targeted 
treatment modalities has opened new ways to 
selectively target these mechanistic pathways in vivo. 
This has taught us that the role of proinfl ammatory 
cytokines, in particular TNFα, is not crucial in the 
immunopathogenesis of pSS. B cells appear to play a 
major role, as depletion of B cells leads to restoration 
of salivary fl ow and is effi  cacious for treatment of 
extraglandular manifestations and mucosa-associated 
lymphoid tissue lymphoma. B cells also orchestrate 
T-cell infi ltration and ductal epithelial dearrangement 
in the salivary glands. Gene profi ling of salivary 
gland tissue in relation to B-cell depletion confi rms 
that the axis of IFNα, B-cell activating factor, B-cell 
activation, proliferation and survival constitutes a major 
pathogenic route in pSS.
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summary of the biologicals that are used, or potentially 
might be used, to treat pSS.
Targeting tumor necrosis factor
As mentioned above, CD4-positive T cells – expressing, 
among others, TNFα – are abundantly present in the 
salivary glands of patients with pSS. Other pro-
inﬂ ammatory cytokines are also over expressed in salivary 
glandular tissue [8]. Furthermore, levels of various 
proinﬂ ammatory cytokines, including TNFα, are elevated 
in peripheral blood and tears of patients with pSS [9,10]. 
In addition to its proinﬂ ammatory and immuno-
modulatory function, TNFα is also involved in direct 
induction of cell death. Indeed, in vitro studies have 
demonstrated the potential of TNF inhibitors to block 
TNFα-mediated apoptosis of salivary gland epithelial 
cells [11]. Th e localization of TNFα-expressing CD4-
positive T cells around ductal epithelial cells also suggests 
their involvement in epi thelial cell apoptosis. Targeting 
TNFα in pSS thus seems justiﬁ ed.
Inﬂ iximab is a therapeutically applied chimeric mono-
clonal IgG1 antibody directed against TNFα. A single-
center, open-label pilot study in 16 patients with pSS 
treated with inﬂ iximab (three infusions of 3 mg/kg at 0, 2, 
and 6 weeks) showed improvement in subjective and 
objective assessments of glandular function after 
12 weeks [12]. With the exception of a slight decrease in 
the erythrocyte sedimentation rate, no signiﬁ cant 
changes in immuno logical parameters were noted. No 
repeat biopsies were performed to demonstrate an eﬀ ect 
on glandular tissue. Ten out of the 16 patients were 
treated with additional infusions of inﬂ iximab for a 
period of 1 year, resulting in a persistent positive eﬀ ect 
on global and local disease manifestations without proof 
of histopathological or immunological changes in disease 
activity [13].
In a further study, four patients underwent labial 
salivary gland biopsies before and 10 weeks after inﬂ ixi-
mab treatment. No change in focus score was reported, 
but the distribution of aquaporin-5, abnormally localized 
at the apical and basolateral membranes of the acinar 
epithelial cells, was restored to localization mainly at the 
apical membranes [14]. Aquaporin-5 is involved in 
passage of cellular water to the lumen of the acinus, and 
abnormal distribution of aquaporin-5 – as seen in pSS 
patients – has therefore been suggested to contribute to 
decreased salivary ﬂ ow. Indeed, restoration of normal 
aquaporin-5 distribution as a consequence of treatment 
with TNF inhibitors coincided with increase of salivary 
ﬂ ow.
Following these pilot studies, a randomized controlled 
trial with inﬂ iximab was performed on 103 patients with 
pSS [15]. Patients received 5 mg/kg inﬂ iximab at weeks 0, 
2, and 6, and were followed for 22 weeks. Th is trial did 
not show any eﬀ ect of inﬂ iximab compared with placebo 
on global and both subjective and objective manifes-
tations of pSS. No changes were seen in the erythrocyte 
sedimentation rate and C-reactive protein levels. Only a 
slight but signiﬁ cant increase in levels of IgM was 
observed in the inﬂ iximab group. In 57 out of the 103 
patients, labial salivary gland biopsies were performed at 
baseline and week 10. No change in focus score was seen 
although a detailed analysis of the histopathology was not 
presented. Of note, also in patients with pSS of recent 
onset, no changes were documented. Apparently, TNFα 
does not play a signiﬁ cant role in the pathogenesis of pSS, 
not at the level of the exocrine glands nor on extra-
glandular manifestations including arthritis. Indeed, TNF 
deﬁ ciency fails to protect development of sicca features 
in a murine model of pSS consisting of BAFF-transgenic 
mice [16]. Th ese data conﬁ rm that TNF, apparently, is not 
a major pathogenic factor in pSS.
Table 1. Biologicals and targets that are used or potentially may be used in primary Sjögren’s syndrome
Target Biological Structure Results trials References
TNFα Infl iximab Chimeric IgG1 mAb No eff ect in RCT [15]
TNFα Etanercept TNF–Rec1–Fc IgG1 fusion protein No eff ect in (small-size) RCT [17,18]
 IFNα Recombinant IFNα2a Increase in unstimulated whole saliva fl ow (RCT) [32]
IFNα Rontalizumab Recombinant human mAb Not performed 
CD20 B cells Rituximab Chimeric IgG1 mAb Subjective and objective improvement of salivary  [39,40]
   fl ow (RCT), decrease in fatigue (RCT)
CD22 B cells Epratizumab Recombinant human mAb Increase in unstimulated whole saliva, decrease in  [45]
   fatigue
BAFF Belimumab  Recombinant human mAb In progress 
BAFF Atacicept TACI–Fc IgG1 fusion protein Not performed 
BAFF Briobacept BAFF–Rec–Fc IgG1 fusion protein Not performed  
CD28-mediated co-stimulation Abatacept CTLA4–Fc IgG1 fusion protein In progress 
BAFF, B-cell activating factor; CTLA4, cytotoxic T-lymphocyte antigen 4; mAb, monoclonal antibody; RCT, randomized controlled trial; Rec, receptor ; TACI, 
transmembrane activator and calcium-modulating cyclophilin ligand interactor.
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Two additional studies using another TNF blocking 
agent, etanercept, in patients with pSS reached the same 
conclusion: no eﬀ ect of blocking TNF was seen in these 
small-sized controlled studies [17,18]. To explain this lack 
of eﬃ  cacy of etanercept, Moutsopoulos and colleagues 
analyzed serum cytokine levels and cellular markers of 
immune activation in pSS patients treated with etaner-
cept [19]. Th ey observed that serum TNFα levels were 
not related to glandular focus scores and that etanercept 
treatment did not restore abnormal immune parameters; 
in contrast, levels of circulating TNFα increased follow-
ing treatment. In addition, IFNα activity and BAFF levels 
also increased following treatment, which may explain 
the lack of eﬃ  cacy of blocking TNFα in pSS [20]. Th e role 
of IFNα is discussed in the next section.
IFNα in primary Sjögren’s syndrome: a double-
edged sword?
Th ere is increasing interest in the role of IFNα in pSS. 
First, case reports have mentioned the development of 
pSS following treatment of chronic viral infections, in 
particular hepatitis B and hepatitis C, with IFNα [21], 
suggesting a role for IFNα in the induction of pSS. 
Indeed, IFNα levels have been reported to be increased 
in plasma of patients with pSS; IFNα mRNA levels were 
increased in their peripheral blood cells, and IFNα-
positive lymphocytes and epithelial cells were detected in 
their labial salivary glands [22,23]. Th e source of inter-
feron is probably the recruitment of plasmacytoid 
dendritic cells to the salivary glands, as shown by Gotten-
berg and colleagues [24]. Sera from pSS patients also 
have high type 1 interferon bioactivity, demonstrated by 
their capacity to induce expression of type 1 interferon-
regulated genes in a monocytic cell line, whereas 
monocytes of pSS patients showed increased expression 
of interferon-inducible genes [25].
Th e origin of this increased IFNα production is not 
clear, but Lövgren and colleagues demonstrated that 
immune complexes or liposomes containing hY1RNA, 
the target of anti-SS-A antibodies, were able to induce 
IFNα production by monocytes and plasmacytoid 
dendritic cells [26]. Importantly, Ittah and colleagues 
subse quently demonstrated that IFNα stimulation of 
salivary gland epithelial cells of patients with pSS 
increased BAFF mRNA expression in these cells signiﬁ -
cantly more than in control salivary gland epithelial cells 
[27]. Stimulation with proinﬂ ammatory cytokines 
resulted in a comparable increase in mRNA expression of 
BAFF in patient cells and control cells. Th ese data suggest 
an increased susceptibility of pSS glandular epithelial 
cells for IFNα. Increased BAFF production plays a major 
role in pSS pathogenesis, as discussed later. Based on 
these data, interference in pSS with monoclonal anti-
bodies to IFNα seems a rational approach. Monoclonal 
antibodies to IFNα are currently available and clinical 
trials in systemic lupus erythematosus and dermato-
myositis/polymyositis are underway. Th ere are strong 
arguments, as discussed above, to design clinical trials 
with these monoclonal antibodies in pSS.
Surprisingly, instead of targeting this proinﬂ ammatory 
cytokine, IFNα itself has been used as a therapeutic agent 
in pSS. Shiozawa and colleagues found an increase in 
saliva production following IFNα treatment (1 x 106 U 
intramuscularly weekly) for 3 months in six pSS patients 
[28]. Comparable ﬁ ndings were obtained in another 
study on 20 pSS patients in which IFNα was compared 
with hydroxy chloro quine; lacrimal and salivary function 
improved by 67% and 61%, respectively, in the IFNα 
group and by 15% and 18%, respectively, in the hydroxy-
chloroquine group [29]. In a second controlled study in 
60 pSS patients, Shiozawa and colleagues used oral IFNα 
(150 IU, three times daily) for 6 months [30]. A signiﬁ cant 
increase in saliva production was observed. Furthermore, 
serial labial salivary gland biopsies in nine patients 
showed a decrease in lymphocytic inﬁ ltration. Th ese data 
were conﬁ rmed in a phase II clinical trial in which oral 
IFNα (in lozenges of 150 IU three times daily) improved 
stimulated whole saliva production during a 12-week 
period [31].
Th is latter study was followed by a phase III random-
ized controlled trial on 497 subjects [32]. IFNα increased 
unstimulated whole saliva ﬂ ow but no signiﬁ cant increase 
was noted in stimulated whole saliva ﬂ ow and oral 
dryness. It is not clear how the increase in salivary ﬂ ow 
following IFNα treatment can be explained. Th e authors 
refer to a study in which incubation of parotid glandular 
tissue with IFNα led to increased expression of 
aquaporin-5, which is involved, as discussed before, in 
passage of water to the lumen of the acinus [33]. 
Improvement of the physiological routes involved in 
saliva production via IFNα might therefore possibly 
underlie the observed outcomes in IFNα trials. An 
immuno modu latory eﬀ ect of IFNα has not been 
convincingly demonstrated.
B-cell-depleting treatment in primary Sjögren’s 
syndrome
As noted before, B-cell hyperactivity is a major ﬁ nding in 
pSS. Although the direct pathophysiological role of 
B cells in glandular tissue destruction in pSS has not been 
fully elucidated, B-cell-targeted treatment has been 
proposed as a therapeutic modality in pSS [34]. Most 
B-cell-depleting therapies target CD20, expressed on 
B  cells from the stage of pre-B cells until the stage of 
activated B cells but not on plasma cells.
An open-label phase II study with the anti-CD20 
monoclonal antibody rituximab (four weekly infusions of 
375 mg/m2) in eight patients with early pSS and in seven 
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patients with pSS and mucosa-associated lymphoid tissue 
lymphoma showed improvement, both subjective and 
objective, in salivary gland function [35]. An increase in 
saliva secretion occurred only in patients with residual 
saliva production (Figure 1). Despite full depletion of 
CD19-positive B lymphocytes from the peripheral blood, 
levels of immunoglobulins did not change – but a 
signiﬁ cant decrease in IgM rheumatoid factor was seen. 
Th e percentage and state of activation of T-cell subsets 
did not change. Peripheral blood B cells had returned 
after 36 weeks (but were still below baseline) and salivary 
ﬂ ow, after initial signiﬁ cant improvement, had declined 
to just above baseline at 48 weeks [36].
Retreatment with rituximab resulted in a clinical and 
biological response fully comparable with that of the 
initial treatment eﬀ ect [36]. In ﬁ ve patients, four of whom 
showed an increased salivary ﬂ ow rate following treat-
ment, parotid biopsies were performed before and 
12 weeks after treatment [37]. Histopathological analysis 
of the biopsies showed a strong reduction of the 
lymphocytic inﬁ ltrate with (partial) disappearance of 
germinal center-like structures. Th e B cell/T cell ratio 
decreased, indicating a higher reduction in B cells than in 
T cells, but B cells were not completely depleted despite 
full depletion from the peripheral blood. Intraepithelial 
lymphocytes in the ducts and the amount and extent of 
lymphoepithelial lesions decreased, demonstrating re-
duc tion in T lymphocytes as well. Most interestingly, 
cellular proliferation of acinar parenchyma decreased 
after treatment, sometimes resulting in normal acinar 
structures (Figure 2). Th ese data demonstrate that B-cell 
depletion via rituximab not only reduces B cells in the 
diseased glands, but also inﬂ uences the presence of 
inﬁ ltrated eﬀ ector T cells – so allowing restoration, at 
least in part, of the architecture of the ducts and acini. 
Th is observation strongly argues for a major role, if not a 
primary role, of B cells in the pathogenesis of pSS.
Following these initial studies several, in part 
controlled, trials – although small in size – have 
conﬁ rmed the eﬃ  cacy of rituximab in pSS. Devauchelle-
Pensec and colleagues treated 16 pSS patients with two 
infusions of rituximab (375 mg/m2) and noted a decrease 
of subjective complaints of dryness, fatigue and arthralgia 
[38]. B cells were strongly reduced in the peripheral 
blood and labial salivary glands but the focus score in the 
gland did not change and neither did the authors observe 
an increase in salivary ﬂ ow, possibly because of the 
already long history of pSS in these patients. Lack of 
salivary ﬂ ow restor a tion following rituximab treatment 
was also observed in the study by Pijpe and colleagues in 
pSS patients with longstanding disease and low levels of 
salivary ﬂ ow [35]. Dass and colleagues performed a 
controlled study on 17 pSS patients with rituximab (1 g 
twice, 2 weeks apart) and noted a signiﬁ cant decrease in 
fatigue persisting for at least 6 months [39]. Unstimulated 
salivary ﬂ ow did not change in this group with 
longstanding pSS (median disease duration 7.25 years).
Longstanding pSS leads to further decrease in saliva 
production (Figure 3), and residual saliva production, as 
mentioned before (Figure 1), is a prerequisite for an 
increase in salivary ﬂ ow following rituximab treatment. 
B-cell depletion was accompanied by a reduction in 
rheumatoid factor, but not in levels of immunoglobulins 
or other autoantibodies. A controlled study on 30 
patients with early pSS using two infusions of rituximab 
(1 g) showed a signiﬁ cant increase in stimulated and 
unstimulated salivary ﬂ ow. Again, a decrease in rheu ma-
toid factor but no change in levels of immunoglobulins 
was noted [40].
All of these studies thus report eﬃ  cacy of rituximab in 
reducing fatigue and extraglandular symptoms including 
arthralgia, whereas an increase in salivary ﬂ ow is depen-
dent on the residual function of the glands that is related 
to disease duration. Since unpublished data from our 
group show that rituximab treatment results in decreased 
serum levels of proinﬂ ammatory cytokines, chemokines 
and adhesion molecules, B cells may play a major role 
also in the global symptoms and extraglandular mani fes-
tations of pSS.
As mentioned above, studying recurrence of B cells 
after B-cell depletion by rituximab oﬀ ers an opportunity 
to analyze the pathogenic events leading to recurrence of 
symptoms. Lavie and colleagues reported the role of 
BAFF in B-cell repopulation after rituximab treatment 
[41]. Th ey observed an increase of serum BAFF and 
BAFF mRNA in peripheral blood mononuclear cells. Th e 
authors concluded that an increase of serum BAFF is 
Figure 1. Stimulated whole saliva secretion following rituximab 
treatment in patients with primary Sjögren’s syndrome. 
Stimulated whole saliva secretion (SWS) at baseline and at 5 and 
12 weeks following rituximab treatment in 14 patients with primary 
Sjögren’s syndrome; an increase in saliva secretion occurred only 
in patients (n = 9) with baseline SWS >0.10 ml/minute and not 
in patients (n = 5) with baseline secretion <0.10 ml/minute. SWS 
consisted of submandibular and sublingual (SM/SL) salivary secretion. 
Reprinted with permission from [35].
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related to disappearance of BAFF receptors after B-cell 
depletion, and that B cells exert negative feedback on 
BAFF production by monocytes – explaining the increase 
of BAFF mRNA in monocytes following B-cell depletion.
Th e role of BAFF in recruiting (autoimmune) B cells in 
pSS has been further explored by Pers and colleagues 
[42]. Th ey observed that serum BAFF levels were 
inversely correlated with the duration of B-cell depletion. 
In some patients repeated labial salivary gland biopsies 
were performed, showing that partial B-cell depletion in 
the glands persisted for at least 12 months and B cells had 
recurred at 24 months. Whereas repopulation of the 
peripheral blood showed increased numbers of mature 
naïve B cells (Bm2 cells) and decreased numbers of 
memory B cells, repopulation of the salivary gland showed 
memory B cells and transitional type 1 B cells as the ﬁ rst 
B cells to be identiﬁ ed. Th ese memory B cells were specu-
lated to be autoreactive. We also observed delayed 
recovery of CD27+ memory B cells in the blood 48 weeks 
after rituximab treatment, whereas the majority of emerg-
ing B cells had a phenotype of transitional B cells [43].
A recent study analyzed gene expression proﬁ le of 
labial salivary glands before and after rituximab treat-
ment and related these proﬁ les to the clinical response on 
rituximab [44]. Interestingly, the authors found two 
groups of genes higher expressed in responders than in 
nonresponders. Th e ﬁ rst group consisted of genes 
involved in the B-cell signaling pathway and the second 
group was related to genes involved in the interferon 
pathway. Th ese data ﬁ t the concept of IFNα-induced 
BAFF expression resulting in B-cell hyperactivity and 
prolonged B-cell survival.
One open-label study targets CD22 on B cells [45]. Th is 
molecule has a more or less similar distribution proﬁ le to 
CD20. Treatment of 16 patients with a monoclonal anti-
CD22 antibody, epratuzumab, resulted in improvement 
of unstimulated whole saliva production and a decrease 
in fatigue in one-half of the patients.
In summary, B cells seem to play a major role in 
orchestrating the pathological immune response in pSS. 
Depleting B cells oﬀ ers a unique possibility to study the 
immunopathogenesis of pSS. BAFF appears as a strong 
stimulant for B-cell activation and proliferation and for 
B-cell survival in pSS.
Targeting BAFF in Sjögren’s syndrome
As mentioned before, BAFF plays a major role in pSS. 
First, mice transgenic for BAFF develop with time a 
clinical presentation of SS with lymphocytic inﬁ ltration 
of the salivary glands [46]. In these mice, marginal zone B 
cells, part of them autoreactive, proliferate in the spleen 
and later inﬁ ltrate the salivary glands. Secondly, levels of 
BAFF are increased in pSS and correlate with titers of 
anti-SS-A and anti-SS-B antibodies [47]. Th irdly, BAFF is 
overexpressed in the salivary glands in pSS [48], and 
BAFF seems to determine B-cell repopulation in the 
peripheral blood and salivary glands of pSS patients 
following rituximab treatment [42].
Targeting BAFF in pSS therefore seems logical. 
Currently, at least three drugs are available for targeting 
BAFF in pSS. First, belimumab – a monoclonal antibody 
Figure 2. Histopathology of parotid gland before and after 
treatment with rituximab in primary Sjögren’s syndrome. 
Comparison of parotid biopsy specimens obtained from a primary 
Sjögren’s syndrome (pSS) patient before rituximab therapy (A1 to 
A4) and 12 weeks after therapy (B1 to AB4). (A1) Before treatment, 
double staining illustrates intense infl ammation (arrows) with highly 
proliferating, large germinal center-like structures (GS; red nuclear 
staining for Ki-67), fully developed lymphoepithelial lesions (LEL; 
brown staining for cytokeratin 14 (CK14)), and reduced glandular 
parenchyma (PAR). (B1) After treatment, infl ammation was reduced 
(arrows), with the absence of GS and the presence of regular 
striated ducts (SD) devoid of lymphoepithelial lesions. (A2) Before 
treatment, there was a dominance of B lymphocytes with GS (CD20) 
in comparison with T lymphocytes (CD3) (A3). (B2) After treatment, 
the lymphoid infi ltrate overall was reduced, with a slight dominance 
of T lymphocytes (CD3) (B3) compared with B lymphocytes 
(CD20). (A4) Higher-magnifi cation view showing fully developed 
lymphoepithelial lesions with many intraepithelial lymphocytes and 
increased basal cell proliferation (arrows), in contrast to the SD after 
therapy with CK14-positive basal cells (B4) (arrows) with regular 
diff erentiation into luminal ductal cells devoid of intraepithelial 
lymphocytes (arrowheads). Original magnifi cation: A1 and B1, x120; 
A2 and B2, x100; A3 and B3, x60; A4 and B4, x200. Reprinted with 
permission from [37].
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to BAFF – is currently under trial (two studies) in 
patients with pSS (NCT01160666 and NCT01008982) 
but data are not yet available. Secondly, atacicept – a 
fusion molecule of IgG–Fc and the extracellular domain 
of TACI (the combined receptor for BAFF and A-
proliferation-inducing ligand) – has not yet been studied 
in pSS. Finally, briobacept – a fusion protein of IgG–Fc 
and the extracellular domain of the BAFF receptor – has 
not yet been used in clinical trials in pSS. Targeting BAFF 
using either belimumab, atacicept or briobacept could 
reveal the pathogenic signiﬁ cance of BAFF in pSS. A 
hurdle to overcome, however, might be the heterogeneity 
of BAFF presentation, either as monomers, homotrimers, 
hetero trimers, splicoforms, or as membrane-bound 
BAFF. Nevertheless this approach is promising. Further-
more, combining the targeting of BAFF with rituximab 
treat ment could enhance and prolong the eﬀ ect of 
rituximab in pSS. Trials with belimumab, atacicept and 
briobacept in pSS are eagerly awaited.
Targeting co-stimulation in Sjögren’s syndrome
Co-stimulation between antigen-presenting cells and 
T cells and between B cells and T cells is an essential step 
in T-cell-dependent immune responses, including auto-
immune responses. Salivary gland epithelial cells in pSS 
have been shown to express HLA class II and co-stimu-
latory molecules and may function as antigen-presenting 
cells in pSS, besides dendritic cells and B cells [49]. 
Interfering in co-stimulation in pSS could, theoretically, 
inhibit both systemic and local autoimmune responses in 
pSS. Abatacept, a fusion molecule of IgG–Fc and cyto toxic 
T-lymphocyte antigen 4, modulates CD28-mediated T-cell 
co-stimulation. A controlled trial with abatacept in pSS 
has been started in the authors’ department, but results 
of treatment with abatacept in pSS are not yet available.
Conclusion
Treatment of SS has been only symptomatic for a long 
time. Th e increasing availability of targeted treatment 
modalities has created possibilities for intervention in 
pathogenic pathways involved in the disease. Th is availa-
bility has not only opened new horizons for treatment, 
but has also provided insight into the pathogenesis of SS. 
In contrast to rheumatoid arthritis, the role of 
proinﬂ ammatory cyto kines – in particular TNFα – is not 
very outspoken in SS, as demonstrated by the lack of 
eﬃ  cacy of TNF blocking. Otherwise, B cells appear to 
play a major role in pSS. Depletion of B cells leads to 
restoration of salivary ﬂ ow and is eﬀ ective for 
extraglandular disease and mucosa-associated lymphoid 
tissue lymphoma. B cells apparently also orchestrate T-
cell inﬁ ltration and ductal epithelial dearrangement in 
Figure 3. Relationship between disease duration and salivary fl ow rates in patients with primary Sjögren’s syndrome. The relationship 
between disease duration (the time from fi rst complaints induced by or related to oral dryness until referral) and mean (standard error of the mean) 
salivary fl ow rates in primary Sjögren’s syndrome (pSS) patients. Normal values are derived from historic controls (n = 36). SM/SL, submandibular/
sublingual glands; UWS, unstimulated whole saliva. *Signifi cant diff erence versus patients with early-onset pSS (≤1-year oral complaints; P <0.005) 
by Mann–Whitney U test. †Signifi cant diff erence versus patients with early-onset pSS (P <0.05) by Mann–Whitney U test. Reprinted with permission 
from [50].
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the glands, as deduced from histo patho logical studies. A 
scenario in which the axis of IFNα, BAFF, B-cell 
activation, proliferation and survival constitutes a basic 
patho genic mechanism in pSS is supported by the results 
of intervention studies currently available. Controlled 
studies targeting IFNα and BAFF are eagerly awaited.
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